TITLE

Vascular endothelial growth factor as a biomarker for the early detection of cancer using a whole cell-based biosensor

AUTHOR(S)
May, Kimberly M. L.; Vogt, Adam; Bachas, Leonidas G.; Anderson, Kimberly W.
PUB. DATE
June 2005
SOURCE
Analytical & Bioanalytical Chemistry;Jun2005, Vol. 382 Issue 4, p1010
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Vascular endothelial growth factor (VEGF) is a cytokine and endothelial cell (EC) mitogen that has been studied for its role in angiogenesis of malignant tumors. Elevated quantities of VEGF in the serum and plasma of patients have been correlated with the presence of cancer and metastasis. Since VEGF induces hyperpermeability of EC monolayers, this protein can be detected in vitro with a whole cell-based biosensor. This biosensor consists of a confluent monolayer of human umbilical vein endothelial cells (HUVECs) attached to a cellulose triacetate (CTA) membrane of an ion-selective electrode (ISE). Previous studies regarding this biosensor have shown that when the biosensor was exposed to a model toxin, such as histamine, the response of the biosensor served as an indirect measurement of the presence of histamine. Similarly, the biosensor responds to the presence of VEGF, but is much more sensitive because VEGF is known to be 50,000-fold more potent than histamine when inducing EC hyperpermeability. The ISE response increased with increasing VEGF concentration. Since lower concentrations required more exposure time, the detection limit was established as a function of exposure time (2–10 h). The practical applicability of the biosensor was also established with cultured human melanoma cells WM793 (nonmetastatic) and 1205LU (metastatic). The resultant change in the potential values revealed significant production of VEGF from the 1205LU cells. A VEGF ELISA was performed to confirm the VEGF concentration in each sample. The biosensor closely predicted the concentrations determined through the ELISA. These results support the use of a cell-based ISE as a quick screening method for the presence of VEGF.
ACCESSION #
17434204

 

Related Articles

  • F-FDG PET and biomarkers for tumour angiogenesis in early breast cancer. Groves, Ashley; Shastry, Manu; Rodriguez-Justo, Manuel; Malhotra, Anmol; Endozo, Raymondo; Davidson, Timothy; Kelleher, Tina; Miles, Kenneth; Ell, Peter; Keshtgar, Mohammed // European Journal of Nuclear Medicine & Molecular Imaging;Jan2011, Vol. 38 Issue 1, p46 

    Purpose: Tumour angiogenesis is an independent and strong prognostic factor in early breast carcinoma. We performed this study to investigate the ability of F-FDG to detect angiogenesis in early breast carcinoma using PET/CT. Methods: Twenty consecutive patients with early (T1-T2) breast...

  • Circulating VEGF as a biomarker for diagnosis of ovarian cancer: a systematic review and a meta-analysis. Bin Liang; Qun He; Liansheng Zhong; Shaocheng Wang; Zhongcheng Pan; Tianjiao Wang; Yujie Zhao // OncoTargets & Therapy;2015, Vol. 8, p1075 

    VEGF is a frequently studied angiogenic factor in ovarian cancer (OC), and is considered to have an important role in the progression of OC. However, its diagnostic value has not been widely accepted because the conclusions are inconsistent and even conflicting. Therefore, we performed a...

  • Detection of circulating vascular endothelial growth factor and matrix metalloproteinase-9 in non-small cell lung cancer using Luminex multiplex technology. YE ZHANG; JIAN-ZHONG WU; JUN-YING ZHANG; JING XUE; RONG MA; HAI-XIA CAO; JI-FENG FENG // Oncology Letters;2014, Vol. 7 Issue 2, p499 

    It has been previously reported that vascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMP)-9 are important for the occurrence and development of non-small cell lung cancer (NSCLC). The present study was designed to detect the serum levels of VEGF and MMP-9 in NSCLC, and to...

  • Clinical Significance of TGF Alpha, TGF Beta1 and VEGF in Sera of Egyptian Patients with Breast Cancer. El Husseini, Motawa E.; Elewa, Fatmaelzahraa Hussein; M., Abdelghani; M., Basma Abdelghany // Egyptian Journal of Hospital Medicine;Jul2013, Vol. 52, p555 

    Background: breast cancer (BC) is the most prevalent cancer among women and affects approximately one million women worldwide each year and it is the most prevalent cancer among Egyptian women and constitutes 29% of National Cancer Institute cases. This study was designed to determine the...

  • Serum Vascular Endothelial Growth Factor (VEGF-C) as a Diagnostic and Prognostic Marker in Patients with Ovarian Cancer. Cheng, Daye; Liang, Bin; Li, Yunhui // PLoS ONE;Feb2013, Vol. 8 Issue 2, p1 

    VEGF-C is regarded as one of the most efficient factors in regulating lymphangiogenesis. The aim of this study was to better understand the role of VEGF-C in the progression of ovarian cancer and to assess its diagnostic and prognostic significance. A total of 109 patients with ovarian cancer,...

  • Lysophosphatidic acid up-regulates vascular endothelial growth factor-C and lymphatic marker expressions in human endothelial cells. Lin, C.-I.; Chen, C.-N.; Huang, M.-T.; Lee, S.-J.; Lin, C.-H.; Chang, C.-C.; Lee, H. // Cellular & Molecular Life Sciences;Sep2008, Vol. 65 Issue 17, p2740 

    Lysophosphatidic acid (LPA) is a low-molecular-weight lipid growth factor, which binds to G-protein-coupled receptors. Previous studies have shown that LPA enhances vascular endothelial growth factor-A (VEGF-A) expression in cancer cells and promotes angiogenesis process. However, the roles of...

  • CA125 Validity a Concern for Assessing Ovarian Cancer Responses to Molecularly Targeted Therapies. Ershler, William B. // Clinical Oncology Alert;May2008, Vol. 24 Issue 5, p39 

    CA125 has become an accepted indicator of epithelial ovarian cancer and is widely-used to monitor patients treated with cytotoxic chemotherapy. However, it remains uncertain how CA125 levels would be affected by molecularly targeted drugs. In this pilot study from Azad and colleagues at the...

  • Sensitive protein detection via triple-binder proximity ligation assays. Schallmeiner, Edith; Oksanen, Elli; Ericsson, Olle; Spångberg, Lena; Eriksson, Susann; Stenman, Ulf-Håkan; Pettersson, Kim; Landegren, Ulf // Nature Methods;Feb2007, Vol. 4 Issue 2, p135 

    The detection of weakly expressed proteins and protein complexes in biological samples represents a fundamental challenge. We have developed a new proximity-ligation strategy named 3PLA that uses three recognition events for the highly specific and sensitive detection of as little as a hundred...

  • Is T790M mutation the key in development of resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)? Takabe, Kazuaki // Journal of Thoracic Disease;Mar2011, Vol. 3 Issue 1, p1 

    An introduction to the journal is presented in which the editor discusses reports published within the issue including one by E. Shash et al on reviewing the role of predictive biomarkers for the optimized use of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) on...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics